Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty
Primary Purpose
Hemolysis
Status
Unknown status
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Propofol
Sponsored by
About this trial
This is an interventional treatment trial for Hemolysis focused on measuring Morbid obesity, General anaesthesia, Propofol, Sevoflurane
Eligibility Criteria
Inclusion Criteria:
- patients between BMI 40-50 kg/m2
Exclusion Criteria:
- patients with BMI under 40 kg/m2 and over 50 kg/m2
- alcohol users
- illicit-drug users
- patients in regular use of anti-depressants, proton bomb inhibitors or calcium canal blockers
- patients transfused either recently, during the intra-operative period or within 10 hours post-operative
- patients previously known to be hypersensitive to any drug that is used during the study
- patients with any psychiatric disorder or dementia
Sites / Locations
- Fundação Centro Médico de Campinas
Outcomes
Primary Outcome Measures
Count erythrocytes
Secondary Outcome Measures
Bilirubins(direct and indirect)
Full Information
NCT ID
NCT00792779
First Posted
November 17, 2008
Last Updated
November 4, 2009
Sponsor
Centro Medico Campinas
1. Study Identification
Unique Protocol Identification Number
NCT00792779
Brief Title
Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty
Official Title
Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty
Study Type
Interventional
2. Study Status
Record Verification Date
November 2009
Overall Recruitment Status
Unknown status
Study Start Date
November 2008 (undefined)
Primary Completion Date
May 2009 (Anticipated)
Study Completion Date
June 2009 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Centro Medico Campinas
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine if propofol could protect erythrocytes by directly scavenging free radicals from the blood current and increasing resistance of their cell membranes in patients submitted to gastroplasty.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemolysis
Keywords
Morbid obesity, General anaesthesia, Propofol, Sevoflurane
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Propofol
Intervention Description
Patients in the Propofol Group (PG) will be induced with target-controlled infusion (TCI) of propofol (Diprifusor, AstraZeneca) and remifentanil (Asena PK, Cardinal Health) at the target dose of 6.0 µg.ml-1 and 8.0 ηg.ml-1, respectively. The patients in the Sevoflurane Group (SG) will be induced with remifentanil TCI at target dose of 8.0 ηg.ml-1 and etomidate 0.5 mg.kg-1 in bolus.
Primary Outcome Measure Information:
Title
Count erythrocytes
Time Frame
After 10 hours post-surgery
Secondary Outcome Measure Information:
Title
Bilirubins(direct and indirect)
Time Frame
After 10 hours post-surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients between BMI 40-50 kg/m2
Exclusion Criteria:
patients with BMI under 40 kg/m2 and over 50 kg/m2
alcohol users
illicit-drug users
patients in regular use of anti-depressants, proton bomb inhibitors or calcium canal blockers
patients transfused either recently, during the intra-operative period or within 10 hours post-operative
patients previously known to be hypersensitive to any drug that is used during the study
patients with any psychiatric disorder or dementia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ricardo F Simoni, MD
Organizational Affiliation
Fundação Centro Médico de Campinas
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fundação Centro Médico de Campinas
City
Campinas
State/Province
São Paulo
ZIP/Postal Code
13084-000
Country
Brazil
12. IPD Sharing Statement
Citations:
PubMed Identifier
11779730
Citation
Tsuchiya M, Asada A, Kasahara E, Sato EF, Shindo M, Inoue M. Antioxidant protection of propofol and its recycling in erythrocyte membranes. Am J Respir Crit Care Med. 2002 Jan 1;165(1):54-60. doi: 10.1164/ajrccm.165.1.2010134.
Results Reference
result
Learn more about this trial
Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty
We'll reach out to this number within 24 hrs